ACM meeting statement, Meeting 21, 4-5 June 2020

Section A: Pre-market registration applications referred for advice

At this meeting, the committee's advice was sought on 6 applications under evaluation by the TGA. The applications included:

• two for the registration of a new chemical entity
• one for the registration of a new biological entity
• two seeking extension of indications
• one seeking a major variation (change in dose form)

Further details of the ACM discussion and advice associated with these items are released within the Australian Public Assessment Reports (AusPARs). Please note that there is a delay from when an application was considered at ACM and the publication of the AusPAR. To browse all AusPARs see: AusPAR search

Further information

For further information on the Advisory Committee on Medicines, please visit: Advisory Committee on Medicines or contact the ACM Secretary by email: ACM@health.gov.au.